Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics

Analysts on Wall Street project that Alcon (ALC) will announce quarterly earnings of $0.71 per share in its forthcoming report, representing a decline of 4.1% year over year. Revenues are projected to reach $2.61 billion, increasing 5.2% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Bearing this in mind, let's now explore the average estimates of specific Alcon metrics that are commonly monitored and projected by Wall Street analysts.Analysts forecast 'Net Sales- Total Surgical' to reach $1.48 billion. The estimate indicates a year-over-year change of +4.3%.The combined assessment of analysts suggests that 'Net Sales- Total Vision care' will likely reach $1.13 billion. The estimate points to a change of +6.6% from the year-ago quarter.Analysts expect 'Net Sales- Total Surgical- Consumables' to come in at $786.91 million. The estimate points to a change of +6.9% from the year-ago quarter.Analysts predict that the 'Net Sales- Total Surgical- Equipment/other' will reach $232.70 million. The estimate indicates a year-over-year change of +4.4%.The consensus among analysts is that 'Net Sales- Total Vision Care- Contact lenses' will reach $682.51 million. The estimate suggests a change of +7.3% year over year.Analysts' assessment points toward 'Net Sales- Total Vision Care- Ocular health' reaching $446.40 million. The estimate indicates a year-over-year change of +5.5%.Based on the collective assessment of analysts, 'Net Sales- Total Surgical- Implantables' should arrive at $464.21 million. The estimate indicates a year-over-year change of +0.1%.It is projected by analysts that the 'Revenues- Other revenues' will reach $17.22 million. The estimate indicates a year-over-year change of +23%.The collective assessment of analysts points to an estimated 'Net sales by region- United States' of $1.18 billion. The estimate indicates a year-over-year change of +3%.According to the collective judgment of analysts, 'Net sales by region- International' should come in at $1.45 billion. The estimate indicates a year-over-year change of +7.9%. View all Key Company Metrics for Alcon here>>> Shares of Alcon have demonstrated returns of -0.5% over the past month compared to the Zacks S&P 500 composite's +3.5% change. With a Zacks Rank #4 (Sell), ALC is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks